Companies

See how salaries can vary from company to company

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood The... view company details

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-C... view company details

We believe the freshest, most consistent milk product ingredients lead to the best tasting end products. And we are the only supplier on the planet whose ultra-fresh milk products can transition from our milking parlors to final packaging within twenty-four hours. Our dedication to freshness results in better tasting, better performing dairy ingredients. Our IdaPro Milk Proteins and Milk Permeate add a new level of Freshness, Flavor, Functionality and Value to applications from yogurt and sports nutrition beverages to soups, sauces and bakery. view company details

IHS Markit is a global leader in information, analytics and solutions for the major industries and markets that drive economies worldwide. Our company partners with clients in business, finance and government to help them see the big picture with unrivaled insights that lead to well-informed, confident decisions. IHS Markit serves more than 50,000 key customers in over 140 countries, including 85 percent of the Fortune Global 500. Headquartered in London, IHS Markit (NYSE: INFO) is committed to sustainable, profitable growth. view company details

InfuCare Rx is a leading data driven nationwide specialty infusion therapy provider focused on treating patients with chronic conditions who require comprehensive clinical management services. Today, many chronic conditions require specialized infusion therapies to help patients lead a healthy and productive lifestyle. InfuCare Rx provides a consistent, coordinated infusion experience for patients in the convenience of their home or alternate care setting. Our dedicated team of pharmacists, nurses and other trained professionals strive to provide optimal patient outcomes through cost effective... view company details

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017.... view company details

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and liver diseases. Its lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase II clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. The company also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS; and ZGN-1345, an orally dosed MetAP2... view company details

LGK is a statewide movement to make Vermont the best place to raise a family and our mission is to ensure affordable access to high-quality child care for all Vermont families by 2025. We work with our partners throughout the state to build high-quality child care and we're calling for more public investment in child care so that it's affordable for families. Together, we will make historic change that will lead to opportunity for our children, families and Vermont's future. view company details

Life.Church is one church in multiple locations, meeting across the United States and globally at Church Online. Our mission is to lead people to become fully devoted followers of Christ. We are risk-taking, irrationally generous, spiritual contributors who bring our best, laugh hard, and honor God with integrity. Visit www.life.church/careers to learn more about the hiring process, take a look at our benefits, and see what it's like to work at Life.Church. view company details

The Los Angeles Homeless Services Authority (LAHSA) is a joint powers authority of the city and county of Los Angeles, created in 1993 to address the problem of homelessness in Los Angeles County. LAHSA is the lead agency in the HUD-funded Los Angeles Continuum of Care, and coordinates and manages over $300 million annually in federal, state, county, and city funds for programs providing shelter, housing, and services to people experiencing homelessness. Apply online for a job in homeless services: https://www.lahsa.org/jobs view company details

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ss-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ss-selective small molecule that is in preclinical trial... view company details

Outlook Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its lead clinical program is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in Phase I clinical trial for the treatment of wet age related macular degeneration. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jer... view company details

Welcome to the LinkedIn page of the Oklahoma Department of Human Services! Follow this page for information about career opportunities and news about DHS. Our mission: We improve the quality of life of vulnerable Oklahomans by increasing people's ability to lead safer, healthier, more independent and productive lives. Our vision: DHS provides help and offers hope to vulnerable Oklahomans through stronger practices, involved communities and a caring and engaged workforce. See our current career opportunities at the following link: https://www.jobapscloud.com/OK/?Keyword=&Loc=&DeptNumber=830000&... view company details

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a re... view company details

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed ... view company details

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase ... view company details

At Potential Inc. our vision is for every person with autism to lead a successful life of value. Our mission as a non-profit organization is to assist children and adults with autism to reach their full educational, social and emotional potential by developing and applying innovative, evidence-based approaches. Potential, Inc. is dedicated to providing high-quality direct services, consultation, community outreach and education for families and professionals. We serve ages 1-64 in our clinic, school, and in the community, schools, and homes. view company details

Ritter Pharmaceuticals, Inc. develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. Its lead product candidate is RP-G28, an orally administered galacto-oligosaccharide that is in Phase III clinical trials for the treatment of lactose intolerance. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California. view company details

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for t... view company details

Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquarte... view company details